STAT Virtual Event | Cancer’s Breakthrough Engine

Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET.

Since the development of Gleevec two decades ago, precision cancer medicines have become a driving force in biotech and a source of hope for cancer patients.

Join STAT’s Adam Feuerstein and our panel of experts as they discuss what has worked best, what hasn’t, and the hottest new approaches in precision cancer medicines, including antibody drug conjugates, tyrosine kinase inhibitors, and more.

Sponsor introduction:

• Axel Hoos, M.D., Ph.D., chief executive officer, Scorpion Therapeutics

Featured speakers:

• Patricia M. LoRusso, DO, Ph.D. (hc), president-elect, American Association for Cancer Research (AACR)
• Suresh S. Ramalingam, M.D., FACP, FASCO, executive director, Winship Cancer Institute of Emory University; associate vice president for cancer, Woodruff Health Sciences Center; Roberto C. Goizueta Chair for Cancer Research
• Vivek Subbiah, M.D., chief, early-phase drug development, Sarah Cannon Research Institute
• Adam Feuerstein, senior writer, biotech, STAT (moderator)

Sponsored By